Literature DB >> 1003407

Potential central nervous system antitumor agents. Aziridinylbenzoquinones.

F Chou, A H Khan, J S Driscoll.   

Abstract

A series of 15 2,5-diaziridinyl-3,6-bis(alkylamino)-1,4-benzoquinone derivatives was synthesized and evaluated as central nervous system antitumor agents in the murine intracerebral L1210 and ependymoblastoma brain tumor systems. Intraperitoneal activity was evaluted in the leukemia L1210, P388, and B16 melanocarcinoma tumor models. The more hydrophilic hydroxyalkylamino compounds were the most effective in the intraperitoneal ascites systems (L1210, P388) with the dihydroxypropylamino (18) and hydroxyethylamino (17) analogues producing long-term survivors. The simple, more lipophilic mono- and dialkylamino derivatives were most effective in the intracerebral systems. Multiple long-term survivors were obtained with the methyl (13), ethyl (14), and dimethylamino (20) compounds in the ependymoblastoma brain tumor system. The parent amino analogue 12 was very active in several tumor models. The relationship between structure, activity, and water solubility are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1003407     DOI: 10.1021/jm00233a010

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Evaluation of response to chemotherapy in retinoblastoma heterotransplanted to the eyes of nude mice.

Authors:  L White; B C Szirth; W F Benedict
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Redox reactions of the FAD-containing apoptosis-inducing factor (AIF) with quinoidal xenobiotics: a mechanistic study.

Authors:  Lina Misevičienė; Zilvinas Anusevičius; Jonas Sarlauskas; Irina F Sevrioukova; Narimantas Cėnas
Journal:  Arch Biochem Biophys       Date:  2011-06-02       Impact factor: 4.013

Review 3.  Diaziquone (AZQ).

Authors:  J F Bender; A J Grillo-Lopez; J G Posada
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

4.  The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.

Authors:  L G Feun; N Savaraj; K Lu; Z Guo; L G Raulston; R S Benjamin; W S Fields; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

5.  Survival and cell cycle kinetics responses of Chinese hamster ovary cells, and clones of human adenocarcinoma of the stomach and astrocytoma to diaziquone (AZQ) in vitro.

Authors:  S C Barranco; G A Schechter; W R Boerwinkle; K A Howell; N H Rubin
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

6.  Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).

Authors:  N Savaraj; K Lu; L G Feun; M E Leavens; D Stewart; M A Burgess; R S Benjamin; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

7.  A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.

Authors:  L G Feun; W K Yung; M E Leavens; M A Burgess; E A Obbens; A Y Bedikian; N Savaraj; D J Stewart; R S Benjamin; W S Fields
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

8.  Superiority of PCNU over AZQ in the treatment of primary brain tumors: results of a prospective randomized trial (81-20) by the Brain Tumor Study Group.

Authors:  M G Malkin; S B Green; D P Byar; T A Strike; P C Burger; F S Vogel; D A Pistenmaa; M S Mahaley; J Ransohoff; W R Shapiro
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Response variability of human brain tumors to AZQ in tissue culture.

Authors:  P L Kornblith; L Rosa; J D Bona; J A Edwards; N Matuzic; A Hirschfeld; C Hawkins
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

10.  Stability of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ; NSC 224070) in aqueous solutions by high-performance liquid chromatography.

Authors:  A G Bosanquet; S B McLoughlin
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.